Cognition Therapeutics Announces Results Of Pre-specified Analysis Of SHINE Study Data Presented At CTAD; Results Show CT1812 Dramatically Slowed Cognitive Decline In Patients With Lower Levels Of Plasma p-tau217, An Important Biomarker Of Alzheimer's Disease Pathology; ADAS-Cog 11 Scores Showed 95% Slowing Of Decline; MMSE Scores Showed 108% Slowing Of Decline
Portfolio Pulse from Benzinga Newsdesk
Cognition Therapeutics announced promising results from their SHINE study, showing that their drug CT1812 significantly slowed cognitive decline in Alzheimer's patients with lower plasma p-tau217 levels. The study results were presented at the CTAD conference, and the company will host an investor webinar to discuss the findings.
October 29, 2024 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cognition Therapeutics' SHINE study results indicate that their drug CT1812 significantly slows cognitive decline in Alzheimer's patients with low plasma p-tau217 levels. This could positively impact the company's stock price.
The SHINE study results are significant as they show CT1812's effectiveness in slowing cognitive decline in Alzheimer's patients, a major breakthrough in treatment. This positive data is likely to boost investor confidence and potentially increase the stock price of Cognition Therapeutics.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100